Article

Experimental Treatment for Diabetic Kidney Disease Based on Precision Medicine

The drug, baricitinib, is a JAK-STAT inhibitor being developed for rheumatoid arthritis. Research by scientists at the Unviersity of Michigan found a key role for the pathway in diabetic patients suffering from kidney disease.

Phase 2 trial results presented at the recently concluded annual meeting of the American Diabetes Association (ADA) narrate a story of how a successful partnership between academia and the pharmaceutical industry has resulted in what could be a precision treatment for diabetic kidney disease.

Scientists at the University of Michigan studying the disease condition identified an overactive JAK/STAT signaling pathway in many kidney cells damaged by hyperglycemia. The JAK/STAT pathway is also activated in individuals suffering from the inflammatory disease of the immune system, rheumatoid arthritis (RA). Scientists at Eli Lilly & Co who were developing baricitinib to inhibit the JAK/STAT pathway in RA, approached the University of Michigan team to test the drug in their kidney disease model. In just over a year, a phase 1 clinical trial was initiated to test the drug in 129 adult patients.

Results presented at ADA from the phase 2 studies showed that the drug reduced a key sign of kidney damage, with few side effects, and it had a sustained impact even after patients stopped taking it.

Read more on ScienceDaily: http://bit.ly/1B5i7dO

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Dr Carla Nester
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Marry Vuong, PharmD, BCPPS
Marry Vuong, PharmD, BCPPS
Dr Sundar Jagannath
Dr Muhammad Faizan
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo